DYNC2I1

Across TCGA pan-cancer cohorts, DYNC2I1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DYNC2I1 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher DYNC2I1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DYNC2I1 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

LSCC, GBM, and PDAC are the cancer types where DYNC2I1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.825	1.000	.003	23	view →
GBM	DFS	Quartile	All	0.460	0.267	.020	2	view →
PDAC	OS	Tertile	All	0.974	0.766	.036	2	view →
CCRCC	DFS	Median	II,III,IV	0.957	0.820	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DYNC2I1–LSCC (DFS)

Open the LSCC breakdown →